G1 Therapeutics, Inc.
G1 Therapeutics, Inc. (GTHX) is a publicly traded company in the Unknown sector. Across all available filings, 31 corporate insiders have executed 432 transactions totaling $96.1M, demonstrating a bearish sentiment with -$45.3M in net insider flow. The most recent transaction on Sep 18, 2024 involved a transaction of 185,358 shares valued at $0.
GTHX Insider Activity Summary
Who Is Buying GTHX Stock?
No significant insider buying has been recorded for GTHX in the recent period.
Who Is Selling GTHX Stock?
No significant insider selling has been recorded for GTHX in the recent period.
Is G1 Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for GTHX is bearish with an Insider Alignment Score of 26/100 and a net flow of -$45.3M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
GTHX Frequently Asked Questions
Understanding GTHX Insider Activity
Insider trading at G1 Therapeutics, Inc. (GTHX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 31 insiders are actively trading GTHX stock, having executed 432 transactions in the past 90 days. The most active insider is Douglas Reed Md (Executive), who has made 14 transactions totaling $42.3M.
Related Tools
Track G1 Therapeutics, Inc. Insider Activity
Get notified when executives and directors at GTHX file new Form 4 transactions